跳至主要内容
临床试验/DRKS00033341
DRKS00033341招募中Unknown

Effects of oxytocin receptor antagonization in migraine: A randomized, double-blind, placebo-controlled human provocation study - oxytocin and migraine

Charité Universtitätsmedizin Berlin0 个研究点目标入组 60 人开始时间: 2024年1月8日最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 45 Years(—)
性别
All

入选标准

  • Group 1: Women with migraine are eligible to be included in the study if all of the following criteria apply:
  • 1. Confirmed episodic migraine based on the criteria of the IHS
  • 2. 1-5 migraine days in the 28 days prior to study enrollment
  • 3. Use of continuous hormonal contraception (i.e., no hormone-free interval) for at least 3 months
  • 4. Age 18-45 years upon entry into screening.
  • Control 1: Men with migraine are eligible to be included in the study if all of the following criteria apply:
  • 1. Confirmed episodic migraine based on the criteria of the International Headache Society (IHS)
  • 1. 1-5 migraine days in the 28 days prior to study enrollment
  • 2. Age 18-45 years upon entry into screening.
  • Control 2: Healthy female controls are eligible to be included in the study if all of the following criteria apply:
  • 1. Use of continuous hormonal contraception (i.e., no hormone-free interval) for at least 3 months
  • 2. Age 18-45 years upon entry into screening.

排除标准

  • Participants are excluded from the study if any of the following criteria apply:
  • 1. History of any primary headache disorder other than migraine without aura (for participants with migraine), or tension-type headache with a frequency of <5 headache days per month before screening according to the IHS criteria, based on medical records and/or patient self-report.
  • 2. History of any secondary headache disorder before screening, based on medical records and/or patient self-report.
  • 3. Intake of prophylactic migraine medication within =30 days or 5 plasma half-lives (whichever is longer) prior to screening.
  • 4. Intake of hormonal treatments other than hormonal contraception.
  • 3. History or evidence of neurological disorders (e.g., multiple sclerosis, brain tumor, history of severe traumatic brain injury, history of brain surgery).
  • 4. History or evidence of severe inflammatory diseases (infectious, rheumatic).
  • 5. Evidence of arterial hypertension.
  • 6. History or evidence of cardiovascular diseases (e.g., cerebral ischemia, coronary heart disease, history of myocardial infarction, peripheral arterial disease, severe heart valve disease).
  • 7. Evidence of Diabetes mellitus.
  • 8. Body Mass Index <18 or >30 kg/m2.
  • 9. Female participants who are pregnant or breastfeeding or plan to become pregnant or breastfeed during participation in the study.
  • 10. History or evidence of severe psychiatric disorders.
  • 11. Previous participation in a provocation study.
  • 12. Initiation of any new medical treatment and/or device during study period results in exclusion.
  • 13. Participants likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participants’ and investigator’s knowledge.

研究者

发起方
Charité Universtitätsmedizin Berlin

相似试验